https://mindmedicinelaw.com/briefing/psilocybin-clinical-trial-reduces-cocaine-use-filament-health-s-exclusive-ip-pos-20260926-44834The Psychedelic Journalen2026-09-27T22:07:07.306503+00:00Psilocybin Clinical Trial Reduces Cocaine Use: Filament Health's Exclusive IP Positionpsilocybin clinical trial, cocaine use disorder, filament health, intellectual property, psychedelic research, substance use treatment, regulatory policy, exclusive data rights, public health, stimulant addictionhttps://mindmedicinelaw.com/briefing/mapping-5-ht2-receptor-allostery-implications-for-psychedelic-drug-design-20260925-44759The Psychedelic Journalen2026-09-27T22:08:02.915304+00:00Mapping 5-HT2 Receptor Allostery: Implications for Psychedelic Drug Design5-ht2 receptor, allosteric modulation, molecular dynamics, psychedelic drug design, serotonin receptor, signaling bias, clinical trial strategy, neuropsychiatric therapeutics, ligand efficacy, drug safetyhttps://mindmedicinelaw.com/briefing/fda-psychedelic-hearing-regulatory-signals-for-u-s-psychiatry-20260925-44835The Psychedelic Journalen2026-09-27T22:07:28.145554+00:00FDA Psychedelic Hearing: Regulatory Signals for U.S. Psychiatryfda psychedelic hearing, psychiatry regulation, clinical trial guidance, psychedelic research policy, schedule i substances, prescriber training, insurance coverage psychedelics, legal risks psychedelics, public hearing fda, psychedelic therapy compliancehttps://mindmedicinelaw.com/briefing/italy-expands-landmark-psychedelic-trial-for-depression-20260925-44836The Psychedelic Journalen2026-09-27T22:07:16.418439+00:00Italy Expands Landmark Psychedelic Trial for Depressionitaly, psychedelic clinical trials, treatment-resistant depression, regulatory policy, european union, psilocybin, public health, mental health research, trial expansion, aifahttps://mindmedicinelaw.com/briefing/psilocybin-assisted-therapy-for-major-depression-evidence-and-policy-in-brazil-20260924-44762The Psychedelic Journalen2026-09-27T22:08:38.647887+00:00Psilocybin-Assisted Therapy for Major Depression: Evidence and Policy in Brazilpsilocybin, major depressive disorder, psychedelic-assisted therapy, brazil, clinical trials, antidepressant effects, policy, adverse events, regulation, mental healthhttps://mindmedicinelaw.com/briefing/ketamine-for-adolescent-trd-clinical-promise-and-safety-gaps-20260924-44776The Psychedelic Journalen2026-09-27T22:08:29.609700+00:00Ketamine for Adolescent TRD: Clinical Promise and Safety Gapsketamine, adolescent depression, treatment-resistant depression, rapid antidepressant, long-term safety, clinical trials, pediatric psychiatry, neuroplasticity, policy implicationshttps://mindmedicinelaw.com/briefing/ayahuasca-diversity-study-reshapes-policy-and-research-standards-20260924-44793The Psychedelic Journalen2026-09-27T22:08:21.138724+00:00Ayahuasca Diversity Study Reshapes Policy and Research Standardsayahuasca, botanical diversity, chemical variability, clinical trial standardization, regulatory frameworks, public health guidance, FDA, psychedelic research, harmine, DMThttps://mindmedicinelaw.com/briefing/age-moderates-psychedelic-mental-health-outcomes-new-evidence-20260924-44723The Psychedelic Journalen2026-09-27T22:08:11.850728+00:00Age Moderates Psychedelic Mental Health Outcomes: New Evidencepsychedelic research, age moderation, mental health outcomes, clinical trial design, psilocybin, LSD, regulatory guidance, public health, mystical experience, naturalistic studyhttps://mindmedicinelaw.com/briefing/first-longitudinal-study-ketamine-assisted-psychotherapy-in-youth-us-2026-20260921-44770The Psychedelic Journalen2026-09-27T22:07:40.631978+00:00First Longitudinal Study: Ketamine-Assisted Psychotherapy in Youth (US, 2026)ketamine-assisted psychotherapy, adolescents, young adults, longitudinal study, depression, suicidality, safety profile, psychedelic research, clinical trials, mental health policyhttps://mindmedicinelaw.com/briefing/psilocybin-clinical-trials-evidence-review-and-u-s-rescheduling-debate-20260918-44827The Psychedelic Journalen2026-09-27T22:07:51.796504+00:00Psilocybin Clinical Trials: Evidence Review and U.S. Rescheduling Debatepsilocybin, clinical trials, rescheduling, controlled substances act, FDA breakthrough therapy, policy implications, safety data, psychedelic therapy, regulatory frameworks